Luoxin Pharmaceuticals Group Stock Co (SZSE:002793) Total Liabilities : ¥2,693 Mil (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Luoxin Pharmaceuticals Group Stock Co Total Liabilities?

Luoxin Pharmaceuticals Group Stock Co's Total Liabilities for the quarter that ended in Mar. 2024 was ¥2,693 Mil.

Luoxin Pharmaceuticals Group Stock Co's quarterly Total Liabilities declined from Sep. 2023 (¥2,800.54 Mil) to Dec. 2023 (¥2,545.00 Mil) but then increased from Dec. 2023 (¥2,545.00 Mil) to Mar. 2024 (¥2,693.09 Mil).

Luoxin Pharmaceuticals Group Stock Co's annual Total Liabilities increased from Dec. 2021 (¥4,761.04 Mil) to Dec. 2022 (¥4,811.64 Mil) but then declined from Dec. 2022 (¥4,811.64 Mil) to Dec. 2023 (¥2,545.00 Mil).

Luoxin Pharmaceuticals Group Stock Co Total Liabilities Historical Data

The historical data trend for Luoxin Pharmaceuticals Group Stock Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luoxin Pharmaceuticals Group Stock Co Total Liabilities Chart

Luoxin Pharmaceuticals Group Stock Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

3,498.81

3,443.96

4,761.04

4,811.64

2,545.00

Luoxin Pharmaceuticals Group Stock Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															3,845.40	3,380.33	2,800.54	2,545.00	2,693.09

Luoxin Pharmaceuticals Group Stock Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Luoxin Pharmaceuticals Group Stock Co's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	1917.556	+	(468.306	+	159.136
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2,545

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	5117.407	-	2572.409
	=	2,545

Luoxin Pharmaceuticals Group Stock Co's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	2247.538	+	(288.697	+	156.852
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	2,693

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	5117.183	-	2424.096
	=	2,693

Luoxin Pharmaceuticals Group Stock Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Luoxin Pharmaceuticals Group Stock Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Luoxin Pharmaceuticals Group Stock Co (SZSE:002793) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luoxin Pharmaceuticals Group Stock Co Ltd (SZSE:002793) » Definitions » Total Liabilities

Traded in Other Exchanges

N/A

Address

85 Faraday Road, Floor 1-3, Building 1, Building 2, Pilot Free Trade Zone, Shanghai, CHN, 201203

Website

http://www.luoxin.cn

Luoxin Pharmaceuticals Group Stock Co Ltd is a pharmaceutical enterprise engaged in research and development, production, and trade of new drugs. It manufactures drugs for various diseases including tumor, respiratory, gastrointestinal, endocrine, cardiovascular, nervous system, antimicrobial infection, among others.

Executives

Ye Bang Mi	Supervisors
Fang Xiu Bao	Directors, executives
Zhu Fu Lin	Directors, executives
Chen Li	Supervisors
Yao Liang	Directors, executives

Luoxin Pharmaceuticals Group Stock Co (SZSE:002793) Headlines

No Headlines